IVI-RMA Madrid, Av del Talgo 68, Madrid, Spain; Alfonso X 'El Sabio' University, Madrid, Spain.
IVI-RMA Madrid, Av del Talgo 68, Madrid, Spain.
Reprod Biomed Online. 2018 Jul;37(1):113-119. doi: 10.1016/j.rbmo.2018.03.015. Epub 2018 Apr 6.
Is anti-Müllerian hormone (AMH) serum concentration a useful tool to predict the outcome of assisted reproductive treatment?
Retrospective cohort study involving 2971 patients who underwent 5570 IVF cycles. Patients were classified into six groups according to their AMH levels and analysed for associations with reproductive outcome. Several parameters of ovarian response and clinical outcome were compared between groups.
Cancellation rate and clinical pregnancy rate varied by AMH group, with highest cancellation rates (32.8%, P = 0.021) and lowest clinical pregnancy rates (9.8%, P < 0.001) in the group with lowest AMH. When these patients achieved embryo transfer, the implantation rate (30.5%) did not significantly differ from the other groups, and retained a low, but reasonable, clinical pregnancy rate per transfer (45.9%). When this group was classified into three female age groups, the clinical pregnancy rate was found to be significantly higher in the patients younger than 37 years (58.1%) compared with patients aged between 37 and 39 years (48.9%) and those aged over 39 years (27%, P < 0.001).
Although significant differences in pregnancy rates were observed among the different AMH groups, even in the lowest AMH level group, the probability of achieving pregnancy was reasonable, especially if the patient's age is not very advanced.
抗苗勒管激素（AMH）血清浓度是否可作为预测辅助生殖治疗结局的有用工具？
回顾性队列研究，纳入 2971 名接受 5570 个 IVF 周期的患者。根据 AMH 水平将患者分为六组，并分析与生殖结局的相关性。比较组间卵巢反应和临床结局的多个参数。
取消率和临床妊娠率因 AMH 组而异，AMH 最低组的取消率最高（32.8%，P = 0.021），临床妊娠率最低（9.8%，P < 0.001）。当这些患者进行胚胎移植时，着床率（30.5%）与其他组无显著差异，且每移植的临床妊娠率保持在较低但合理的水平（45.9%）。当将该组分为三个女性年龄组时，发现年龄小于 37 岁的患者的临床妊娠率（58.1%）明显高于 37-39 岁的患者（48.9%）和年龄大于 39 岁的患者（27%，P < 0.001）。
尽管不同 AMH 组的妊娠率存在显著差异，但即使在 AMH 最低水平组，妊娠的可能性也较为合理，特别是如果患者的年龄不是非常大。
